Picture BIO.NRW Greener Manufacutring Show 2023 Köln 650x100px
Document › Details

DiaSorin S.p.A.. (4/21/17). "Press Release: DiaSorin Receives Authorization for the Distribution of Zika IgM Test in Europe". Saluggia.

Region Region EU (European Union)
Organisations Organisation DiaSorin S.p.A. (FTSE Italia Mid Cap: DIA)
  Group DiaSorin (Group)
  Organisation 2 EU (govt)
Products Product Liaison® XL Zika Capture IgM assay
  Product 2 Liaison XL analyzer
Persons Person Fava, Riccardo (DiaSorin 201607 IR + Corporate Communications Director)
  Person 2 Di Terlizzi, Ines (DiaSorin 201607 Investor Relations)

DiaSorin (FTSE Italia Mid Cap: DIA) is pleased to announce that it has received the authorization for the distribution of LIAISON® XL Zika Capture IgM assay in Europe.

After the Emergency Use Authorization (EUA) received in the United States some weeks ago, DiaSorin will also now start to distribute the Zika IgM test in Europe.

LIAISON® XL Zika Capture IgM assay is the first-of-its-kind fully-automated serology assay for the detection of Zika virus infections.

The most common symptoms of Zika are fever, rash, joint pain, and conjunctivitis, or red eyes. The illness usually is mild with symptoms lasting for several days to a week. People typically do not get sick enough to require hospitalization and they very rarely die of Zika: however, the virus infection during pregnancy can cause a serious birth defect called microcephaly, as well as other severe fetal brain defects.

Funding for the LIAISON® XL Zika Capture IgM assay was provided by the U.S. Department of Health and Human Services, which granted DiaSorin a $2.6 million contract in the fall of 2016.

About DiaSorin Group

Headquartered in Italy and listed in the FTSE Mid Cap Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field. For over 40 years the Company has been developing, producing and marketing reagent kits for IVD worldwide. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnostics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnostics market and new tests in the molecular diagnostics markets, which identify DiaSorin Group as the IVD “Diagnostics Specialist.”

For additional information, please contact:

Riccardo Fava
Investor Relations & Corporate Communication Senior Director
Tel: +39.0161.487988

Ines Di Terlizzi
Investor Relator
Tel: +39.0161.487567

Record changed: 2023-06-05


Picture EBD Group ChinaBio Partnering Forum 2023 Shanghai 650x200px

More documents for DiaSorin (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group BIO-Europe 2023 Munich BEU23 650x300px

» top